-
Je něco špatně v tomto záznamu ?
Nitrated fatty acids suppress angiotensin II-mediated fibrotic remodelling and atrial fibrillation
TK. Rudolph, T. Ravekes, A. Klinke, K. Friedrichs, M. Mollenhauer, M. Pekarova, G. Ambrozova, H. Martiskova, JJ. Kaur, B. Matthes, A. Schwoerer, SR. Woodcock, L. Kubala, BA. Freeman, S. Baldus, V. Rudolph,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1996-01-01 do Před 1 rokem
PubMed
26598510
DOI
10.1093/cvr/cvv254
Knihovny.cz E-zdroje
- MeSH
- akční potenciály účinky léků MeSH
- angiotensin II farmakologie MeSH
- dusíkaté sloučeniny farmakologie MeSH
- fibrilace síní prevence a kontrola MeSH
- fibróza MeSH
- konexin 43 analýza MeSH
- kultivované buňky MeSH
- kyseliny linolové farmakologie MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- protein Smad2 antagonisté a inhibitory MeSH
- remodelace síní účinky léků MeSH
- srdeční síně patologie MeSH
- transdiferenciace buněk účinky léků MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
AIM: Atrial fibrosis, one of the most striking features in the pathology of atrial fibrillation (AF), is promoted by local and systemic inflammation. Electrophilic fatty acid nitroalkenes, endogenously generated by both metabolic and inflammatory reactions, are anti-inflammatory mediators that in synthetic form may be useful as drug candidates. Herein we investigate whether an exemplary nitro-fatty acid can limit atrial fibrosis and AF. METHODS AND RESULTS: Wild-type C57BL6/J mice were treated for 2 weeks with angiotensin II (AngII) and vehicle or nitro-oleic acid (10-nitro-octadec-9-enoic acid, OA-NO2, 6 mg/kg body weight) via subcutaneous osmotic minipumps. OA-NO2 significantly inhibited atrial fibrosis and depressed vulnerability for AF during right atrial electrophysiological stimulation to levels observed for AngII-naive animals. Left atrial epicardial mapping studies demonstrated preservation of conduction homogeneity by OA-NO2. The protection from fibrotic remodelling was mediated by suppression of Smad2-dependent myofibroblast transdifferentiation and inhibition of Nox2-dependent atrial superoxide formation. CONCLUSION: OA-NO2 potently inhibits atrial fibrosis and subsequent AF. Nitro-fatty acids and possibly other lipid electrophiles thus emerge as potential therapeutic agents for AF, either by increasing endogenous levels through dietary modulation or by administration as synthetic drugs.
Department of Pharmacology and Chemical Biology University of Pittsburgh Pittsburgh PA USA
Institute of Biophysics Academy of Sciences of the Czech Republic v v 1 Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000852
- 003
- CZ-PrNML
- 005
- 20170116093002.0
- 007
- ta
- 008
- 170103s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/cvr/cvv254 $2 doi
- 024 7_
- $a 10.1093/cvr/cvv254 $2 doi
- 035 __
- $a (PubMed)26598510
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rudolph, Tanja K $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
- 245 10
- $a Nitrated fatty acids suppress angiotensin II-mediated fibrotic remodelling and atrial fibrillation / $c TK. Rudolph, T. Ravekes, A. Klinke, K. Friedrichs, M. Mollenhauer, M. Pekarova, G. Ambrozova, H. Martiskova, JJ. Kaur, B. Matthes, A. Schwoerer, SR. Woodcock, L. Kubala, BA. Freeman, S. Baldus, V. Rudolph,
- 520 9_
- $a AIM: Atrial fibrosis, one of the most striking features in the pathology of atrial fibrillation (AF), is promoted by local and systemic inflammation. Electrophilic fatty acid nitroalkenes, endogenously generated by both metabolic and inflammatory reactions, are anti-inflammatory mediators that in synthetic form may be useful as drug candidates. Herein we investigate whether an exemplary nitro-fatty acid can limit atrial fibrosis and AF. METHODS AND RESULTS: Wild-type C57BL6/J mice were treated for 2 weeks with angiotensin II (AngII) and vehicle or nitro-oleic acid (10-nitro-octadec-9-enoic acid, OA-NO2, 6 mg/kg body weight) via subcutaneous osmotic minipumps. OA-NO2 significantly inhibited atrial fibrosis and depressed vulnerability for AF during right atrial electrophysiological stimulation to levels observed for AngII-naive animals. Left atrial epicardial mapping studies demonstrated preservation of conduction homogeneity by OA-NO2. The protection from fibrotic remodelling was mediated by suppression of Smad2-dependent myofibroblast transdifferentiation and inhibition of Nox2-dependent atrial superoxide formation. CONCLUSION: OA-NO2 potently inhibits atrial fibrosis and subsequent AF. Nitro-fatty acids and possibly other lipid electrophiles thus emerge as potential therapeutic agents for AF, either by increasing endogenous levels through dietary modulation or by administration as synthetic drugs.
- 650 _2
- $a akční potenciály $x účinky léků $7 D000200
- 650 _2
- $a angiotensin II $x farmakologie $7 D000804
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a fibrilace síní $x prevence a kontrola $7 D001281
- 650 _2
- $a remodelace síní $x účinky léků $7 D064752
- 650 _2
- $a transdiferenciace buněk $x účinky léků $7 D054338
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a konexin 43 $x analýza $7 D018031
- 650 _2
- $a fibróza $7 D005355
- 650 _2
- $a srdeční síně $x patologie $7 D006325
- 650 _2
- $a kyseliny linolové $x farmakologie $7 D008041
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a dusíkaté sloučeniny $x farmakologie $7 D009574
- 650 _2
- $a protein Smad2 $x antagonisté a inhibitory $7 D051899
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ravekes, Thorben $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
- 700 1_
- $a Klinke, Anna $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany International Clinical Research Center-Center of Biomolecular and Cellular Engineering, St Anne's University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Friedrichs, Kai $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
- 700 1_
- $a Mollenhauer, Martin $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
- 700 1_
- $a Pekarova, Michaela $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic.
- 700 1_
- $a Ambrozova, Gabriela $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic. $7 gn_A_00005405
- 700 1_
- $a Martiskova, Hana $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic.
- 700 1_
- $a Kaur, Jatinder-Jit $u Department of Cardiology, University Heart Center Hamburg, University Hospital Eppendorf, Hamburg, Germany.
- 700 1_
- $a Matthes, Bianca $u Department of Cardiology, University Heart Center Hamburg, University Hospital Eppendorf, Hamburg, Germany.
- 700 1_
- $a Schwoerer, Alex $u Department of Cellular and Integrative Physiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany DZHK (German Centre for Cardiovascular Research)-Hamburg/Kiel/Luebeck, Hamburg, Germany.
- 700 1_
- $a Woodcock, Steven R $u Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
- 700 1_
- $a Kubala, Lukas $u International Clinical Research Center-Center of Biomolecular and Cellular Engineering, St Anne's University Hospital Brno, Brno, Czech Republic Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic.
- 700 1_
- $a Freeman, Bruce A $u Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
- 700 1_
- $a Baldus, Stephan $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
- 700 1_
- $a Rudolph, Volker $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany volker.rudolph@uk.koeln.de.
- 773 0_
- $w MED00009440 $t Cardiovascular research $x 1755-3245 $g Roč. 109, č. 1 (2016), s. 174-84
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26598510 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170116093107 $b ABA008
- 999 __
- $a ok $b bmc $g 1179992 $s 961419
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 109 $c 1 $d 174-84 $e 20151123 $i 1755-3245 $m Cardiovascular Research $n Cardiovasc Res $x MED00009440
- LZP __
- $a Pubmed-20170103